Top Viral Diseases to Watch in 2026
Updated: Sep 2
Written by Dr. Charles Drew, Lead Pharmaceutical Content Specialist & Clinical Drug Information Reviewer
Reviewed for medical accuracy under the Ivermectinkart Editorial Policy
Introduction
Viral disease surveillance in 2026 is not centered on one single threat. The top viral diseases to watch in 2026 include familiar infections making a comeback, viruses crossing from animals into people, mosquito-borne diseases, and outbreaks that remain geographically concentrated but require rapid public-health action. Measles has resurged in several places, mpox continues to circulate internationally, and avian influenza viruses remain under close surveillance at the human–animal interface. Nipah virus, poliovirus, COVID-19, dengue, yellow fever, and filoviruses also deserve attention for different reasons.
Importantly, “watch” does not mean that every disease poses the same risk to every person or that another pandemic is expected. Here is what current 2026 surveillance tells us, why these viruses matter, and what individuals can realistically do to reduce their risk.
Which Viral Diseases Are Most Important to Watch in 2026?
There is no official universal ranking of the most dangerous viruses in 2026. A useful watchlist instead considers current outbreaks, changes in geographic spread, opportunities for animal-to-human transmission, vaccination gaps, disease severity, and the ability of public-health systems to contain transmission.
Based on current surveillance, several diseases deserve particular attention.
Major viral diseases and viral threats being closely watched in 2026
Viral disease or threat | Why it is being watched | Main transmission route | 2026 perspective |
Measles | Outbreaks linked partly to immunity gaps | Airborne | Preventable with highly effective vaccination |
Avian influenza A(H5) | Continued circulation in animals with sporadic human infections | Mainly infected animals/environment | WHO currently assesses global public-health risk from HPAI A(H5) as low |
Mpox | Continued international circulation and viral evolution | Mainly close physical contact | Ongoing global surveillance |
Nipah virus | Recurrent zoonotic spillover and severe disease | Animals, contaminated food and close contact | Cases reported in India and Bangladesh in 2026 |
Poliovirus | Wild and vaccine-derived viruses continue circulating | Mainly faecal–oral | International spread remains a PHEIC |
COVID-19 | SARS-CoV-2 continues circulating and evolving | Respiratory | Global activity was low by mid-2026, but surveillance continues |
Dengue/yellow fever | Mosquito-borne viruses remain active in multiple regions | Infected mosquitoes | Risk varies greatly by geography and season |
Ebola disease | Major Bundibugyo virus outbreak reported in Central/East Africa | Direct contact with infected bodily fluids | Requires intensive outbreak control |
Why Is Measles Back on the Watchlist?
Measles deserves attention in 2026 because this extremely contagious viral infection can spread rapidly when vaccination coverage falls and susceptible people cluster together. It is not an emerging virus—the concern is the return of a disease that vaccination can largely prevent.
The United States provides a clear example. CDC reported 2,465 confirmed measles cases in 2026 as of August 6, with cases reported across 47 jurisdictions. The CDC's 2026 measles outbreak data are updated as new confirmed cases are reported.
Why vaccination gaps matter
Measles spreads through the air when an infected person breathes, coughs, or sneezes. The virus is so contagious that outbreaks can expand quickly among groups with insufficient immunity.
Typical symptoms include fever, cough, runny nose, red or watery eyes, followed by a characteristic rash. Complications can include pneumonia and inflammation of the brain, and severe illness is more concerning in young children, pregnant people, and people with weakened immune systems.
Measles vaccination therefore remains one of the most important defenses. An outbreak should not be interpreted as evidence that vaccination has stopped working; outbreaks commonly exploit gaps in population immunity.
Why Are Avian Influenza, Mpox, and Nipah Being Monitored?
These infections illustrate three different reasons scientists monitor viruses closely: animal-to-human spillover, continued international transmission, and the possibility that viral characteristics or transmission patterns may change.
Avian influenza A
Highly pathogenic avian influenza A viruses continue circulating in animal populations and occasionally infect people. This makes them important zoonotic viruses—viruses capable of moving between animals and humans.
The WHO assessment of avian influenza A , published in May 2026 using data through March 1, assessed the global public-health risk as low. Risk for people with occupational or frequent exposure to potentially infected animals was assessed as low to moderate depending on local circumstances and protective measures.
WHO also reported new human detections of animal influenza viruses during 2026. Crucially, sustained human-to-human transmission of recent A viruses has not been identified.
That distinction matters. Continued animal outbreaks and occasional human infections justify intensive surveillance, but they do not mean that H5N1 is currently spreading efficiently between people.
Mpox
Mpox remains another disease requiring international monitoring. WHO continued publishing multi-country outbreak situation reports during 2026.
Scientists are also monitoring viral evolution. In February 2026, WHO reported two cases involving a recombinant monkeypox virus containing genomic elements from clades Ib and IIb. Recombination can occur when related viruses exchange genetic material.
The finding did not establish that the recombinant virus was more dangerous. Both reported cases had clinical presentations similar to those associated with other clades, demonstrating why genomic findings need careful interpretation rather than alarming conclusions.
Mpox spreads mainly through close contact with an infected person, including contact with lesions, bodily fluids, contaminated materials, and certain forms of prolonged close interaction.
Nipah virus
Nipah remains rare but closely monitored because infection can cause severe neurological disease and outbreaks can result from animal-to-human spillover followed, in some circumstances, by person-to-person transmission.
WHO reported two epidemiologically linked cases in West Bengal, India, early in 2026 and another laboratory-confirmed case in Kerala in June. Bangladesh also reported a confirmed Nipah infection in January 2026.
The WHO 2026 Nipah virus update for India reported that the June Kerala event involved one confirmed case and no identified secondary transmission at the time of the assessment. WHO considered the regional and global risks low.
Nipah therefore demonstrates an important principle: a virus can deserve intensive surveillance because of its severity and outbreak potential without posing a high global risk at that moment.
A virus appearing on a public-health “watchlist” does not mean an outbreak will become a pandemic. Surveillance is designed to detect changes early—such as increasing cases, geographic spread, animal-to-human spillover, new transmission patterns, or changes in the virus—so health authorities can respond before risks become larger.
Which Established Viral Diseases Still Need Close Attention?
Emerging viruses often receive the most headlines, but established infections can create a greater public-health burden when vaccination falls, mosquito exposure increases, or surveillance and healthcare access are disrupted.
Poliovirus
Polio remains particularly important because eradication is close but incomplete.
In August 2026, WHO determined that the international spread of wild poliovirus type 1 and circulating vaccine-derived polioviruses continued to constitute a Public Health Emergency of International Concern, or PHEIC.
As of April 30, 2026, wild poliovirus type 1 had recently been detected in Afghanistan and Pakistan. WHO also reported 32 cases of circulating vaccine-derived poliovirus across 12 countries during the first four months of 2026.
The term “vaccine-derived” can be confusing. These outbreaks are associated with weakened poliovirus strains originally used in oral vaccines that, in communities with inadequate vaccination coverage, can circulate long enough to genetically change. High population immunity prevents both wild and vaccine-derived poliovirus from spreading effectively.
COVID-19
COVID-19 has not disappeared. SARS-CoV-2 continues to circulate globally, although the disease situation in 2026 is very different from the early pandemic years.
WHO reported that global SARS-CoV-2 circulation measured through available surveillance had declined considerably by June 2026. Global test positivity was 1.7% for the week ending June 21, although WHO cautioned that surveillance data are affected by underreporting and differences between countries.
None of the SARS-CoV-2 variants being monitored at that time showed evidence of increased public-health risk.
Continued surveillance remains important because the virus evolves and because COVID-19 can still cause severe illness, particularly among older adults and people with certain underlying conditions. Post-COVID-19 condition, often called long COVID, also remains an area of medical and public-health concern.
What Mosquito-Borne and Hemorrhagic Viral Diseases Matter in 2026?
Dengue, yellow fever, and filovirus outbreaks show why geography matters when discussing viral risk.
These diseases may pose substantial threats in affected regions without representing equal risk worldwide.
Dengue remains a major mosquito-borne concern
Dengue is transmitted primarily by infected Aedes mosquitoes and occurs widely in tropical and subtropical regions. Most infections are mild or asymptomatic, but some people develop severe dengue, which can involve bleeding, shock, or organ impairment.
Risk changes with mosquito populations, rainfall, temperature, population immunity, travel, and local transmission. This means dengue risk should be assessed using current local public-health information rather than a single global number.
Yellow fever activity continues
Yellow fever is another mosquito-borne viral disease being monitored in 2026. WHO reported continuing transmission activity in both Africa and the Americas during the first part of the year.
Unlike many emerging viral threats, yellow fever has a highly effective vaccine. For people living in or traveling to areas where vaccination is recommended or required, checking current destination-specific guidance is an important preventive step.
Ebola disease caused by Bundibugyo virus
A major outbreak of Ebola disease caused by Bundibugyo virus was reported in the Democratic Republic of the Congo in 2026, with linked cases also reported in Uganda and internationally evacuated healthcare and humanitarian workers.
By July 15, WHO reported 2,124 confirmed cases and 828 deaths in the Democratic Republic of the Congo. These figures describe a serious regional outbreak rather than widespread community transmission worldwide.
Filoviruses such as Ebola require rapid case detection, isolation, contact tracing, infection-control measures, safe care practices, and strong healthcare surveillance.
How Can People Reduce Their Risk From Viral Diseases in 2026?
There is no single action that prevents every viral disease. The most effective approach depends on how the virus spreads and whether a vaccine, antiviral medicine, or other preventive intervention is available.
For many adults, the most practical steps are straightforward:
Keep recommended routine and travel vaccinations up to date.
Follow local outbreak notices when traveling or when cases are reported nearby.
Avoid direct contact with sick or dead wild birds and other animals in areas experiencing animal outbreaks.
Use appropriate mosquito protection in dengue and yellow-fever risk areas.
Practice good respiratory hygiene when experiencing respiratory symptoms.
Wash hands appropriately, particularly around food preparation and patient care.
Follow healthcare infection-control instructions if exposed to a serious communicable disease.
Seek medical advice promptly after a significant exposure or when severe symptoms develop.
Prevention differs according to how viral diseases spread
Transmission pattern | Examples | Useful preventive measures | What to remember |
Airborne/respiratory | Measles, COVID-19 | Vaccination where recommended, ventilation and situation-specific precautions | Prevention depends on the individual virus and exposure |
Mosquito-borne | Dengue, yellow fever | Repellent, protective clothing, mosquito control; vaccination where recommended and available | Risk varies strongly by location and season |
Animal-to-human | Avian influenza, Nipah | Avoid high-risk animal exposures and contaminated food; use occupational protection | Most exposed people do not automatically become infected |
Close physical contact | Mpox | Avoid contact with infectious lesions/materials; follow vaccination guidance when eligible | Risk depends strongly on exposure |
Faecal–oral | Poliovirus | Vaccination, sanitation and hygiene | Population vaccination is central to preventing circulation |
Bodily fluids/direct contact | Ebola disease | Infection-control procedures and avoiding unprotected contact | Specialized outbreak measures are essential |
When Should a Possible Viral Infection Need Medical Care?
Many viral infections cause mild symptoms, but some require prompt medical assessment. The symptoms that matter depend on the virus, your health, recent travel, vaccination status, and possible exposures.
Seek urgent medical care for warning signs such as difficulty breathing, confusion, loss of consciousness, seizures, severe weakness, persistent chest pain, signs of shock, significant bleeding, severe dehydration, or rapidly worsening illness.
Contact a healthcare professional promptly if you develop fever or other concerning symptoms after known exposure to a serious viral infection, recent travel to an outbreak area, contact with potentially infected animals, or a mosquito exposure in an area experiencing transmission.
If a highly contagious or serious infection such as measles, mpox, Nipah, or Ebola is suspected, contact the healthcare facility before arriving when possible. This allows staff to arrange appropriate infection-control precautions and reduce exposure to other patients.
Conclusion
The top viral diseases to watch in 2026 are not all threats of the same size. Measles resurgence, continuing mpox transmission, avian influenza at the human–animal interface, Nipah spillover, persistent poliovirus circulation, mosquito-borne infections, COVID-19, and regional filovirus outbreaks each require different public-health responses.
For most people, the practical message is preparedness rather than alarm. Keep recommended vaccinations current, follow reliable local outbreak information, take travel and mosquito precautions where relevant, and seek medical care after significant exposures or severe symptoms. Viral-disease conditions can change quickly, so current WHO, national public-health, or clinician guidance should take priority over older online information.
Frequently Asked Questions
1. What is the biggest viral disease threat in 2026?
There is no single virus that represents the greatest risk everywhere. Risk depends on geography, exposure, vaccination coverage, age, health, and current outbreaks. Measles, avian influenza, mpox, Nipah, polio, mosquito-borne viruses, and regional filovirus outbreaks are being monitored for different reasons.
2. Is H5N1 bird flu becoming a human pandemic?
Current evidence does not show sustained human-to-human transmission of recent H5 viruses. WHO assessed the global public-health risk from highly pathogenic avian influenza A(H5) as low in its May 2026 assessment. Continued animal circulation nevertheless makes surveillance and protection of exposed workers important.
3. Why is measles still a concern when there is a vaccine?
Measles can return when vaccination coverage falls and enough susceptible people are exposed. Because the virus is exceptionally contagious, outbreaks can spread quickly within under-immunized communities. Maintaining recommended vaccination coverage remains the main strategy for preventing outbreaks and serious complications.
4. Is COVID-19 still circulating in 2026?
Yes. SARS-CoV-2 continues to circulate, although WHO reported low global activity by mid-2026 based on available surveillance. COVID-19 can still cause severe illness in higher-risk individuals, and viral evolution and post-COVID-19 condition remain reasons for continued monitoring.
5. Should travelers worry about dengue and yellow fever in 2026?
Travelers should assess these diseases according to their destination rather than assuming universal risk. Dengue and yellow fever transmission varies substantially by country and season. Before travel, check current health notices, mosquito precautions, and whether yellow-fever vaccination is recommended or required.
6. Does a new viral outbreak mean another pandemic is coming?
No. Most outbreaks do not become pandemics, and some remain limited to individual communities or regions. Public-health agencies investigate outbreaks precisely so they can identify transmission patterns, trace contacts, monitor viral changes, and introduce control measures before wider spread occurs.
Comments